Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab With or Without Radiation in Metastatic Colorectal and NSCLC
NCT02888743Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2017
- Primary completion
- Dec 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 2
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in colorectal cancer (CRC), non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Started Aug 2017; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
colorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02888743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02888743.